HCA Healthcare, Inc. (HCA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

HCA reiterated that it is assuming a 15% to 20% decline in exchange volume, with a first-quarter decline of about 15% already observed. Management said much of the lost volume is expected to shift to uninsured patients, with some offset from employer-sponsored insurance, implying a roughly $600 million to $900 million adjusted EBITDA headwind embedded in the year bridge. The update suggests a cautious but not materially worse-than-expected outlook versus the $750 million midpoint.

Analysis

The setup is less about a near-term earnings miss and more about margin elasticity: if exchange attrition is running at the high end of management’s range, HCA’s revenue hit is only partially offset by mix and acuity, while the fixed-cost structure amplifies the EBITDA impact. The second-order implication is that investors should look past the headline insured/uninsured mix and focus on how quickly self-pay and bad-debt assumptions are normalized in guidance; that’s where the model can still drift lower over the next 1-2 quarters.

The market may also be underestimating competitive spillovers. As exchange patients roll off, the pressure shifts to county systems, safety-net hospitals, and out-of-market regional providers, which can see incremental volume but at weaker reimbursement and worse working capital, creating a lagged deterioration in sector-wide cash conversion. For HCA specifically, the risk is that volume shortfall is not fully recoverable in the back half because disenrolled patients do not reappear in the system; once lost, a meaningful portion becomes structurally displaced rather than temporarily deferred.

The key catalyst is not the current-quarter print but whether management narrows or widens the full-year bridge at the next update. If the decline persists near 15% rather than trending toward the low end of the 15%-20% assumption, consensus EBITDA still has room to come down another low-single-digit percent, which can matter materially for a high-quality defensive name priced on durability. The contrarian view is that the market may already be discounting a moderate headwind, so a short may only work if utilization softness is broader than exchange expirations and starts to hit commercial volumes or elective procedure mix.

Key Decisions for Investors

• Hold a tactical underweight/short HCA into the next update if exchange attrition remains near the current run-rate; target a 3-5% downside move on any guidance reset, with a tight stop if management confirms stabilization.
• Pair trade: short HCA vs long THC over 1-3 months to express relative-pressure on large-system margin compression while retaining upside if safety-net reimbursement improves; risk/reward favors the cheaper, higher-leverage balance sheet on the long leg.
• Buy near-dated HCA puts or put spreads around the next quarterly print to monetize a possible downward revision in the EBITDA bridge; use spreads to limit theta if management stays within the existing range.
• For longer-only portfolios, rotate a portion of healthcare-services exposure from HCA into names less exposed to exchange churn, as the revenue headwind can persist for multiple quarters and the market may still be underpricing the lag in bad-debt normalization.